In CRC their expressions are strongly correlated with each other and, along with TIGIT and BTLA, are tightly associated with markers of T lymphocytes and cNK cells, in which they can inhibit receptor dependent activation (60), thereby dampening anti-tumor effector functions. The gene discussed is BTLA; the disease is colorectal carcinoma.